Key Highlights
● Priority Review Granted:: The FDA accepted with Priority Review Pharming's supplemental New Drug Application to extend Joenja to APDS patients aged 4 and older weighing between 13 and 27 kilograms.
● PDUFA Date:: The FDA set a target action date of January 30, 2027.
● Clinical Support:: The application is supported by an open-label, multinational, single-arm Phase 3 study lasting 12 weeks that showed reduced lymphadenopathy and increased naive B cells in the relevant population.
● Prior Approvals:: Joenja was first approved in March 2023 for patients 12 and older, and the approval was expanded in September 2026 to children ages 4 to 11 weighing at least 27 kilograms.
Pharming Group N.V. (NASDAQ:PHAR) said in a 6-K filed September 25, 2026 that the U.S. Food and Drug Administration accepted, with Priority Review, its supplemental New Drug Application seeking to extend the use of Joenja (leniolisib) to patients with activated PI3K-delta syndrome (APDS) aged 4 and older who weigh between 13 and 27 kilograms. The FDA set a target action date, known as the PDUFA date, of January 30, 2027.
What Priority Review Means Here
Priority Review is an FDA designation reserved for applications that, if approved, would offer significant improvements over existing therapy, and it shortens the agency's standard review timeline. For Pharming, acceptance with Priority Review moves the sNDA toward a decision roughly four months sooner than the standard review track would allow, with the January 30, 2027 PDUFA date marking the point by which the FDA aims to complete its review and act on the application.
Extending Joenja to Younger, Smaller Children
Joenja was first approved by the FDA in March 2023 for adults and adolescents 12 and older with APDS. The company expanded that approval in September 2026 to children ages 4 to 11 weighing at least 27 kilograms. This latest supplemental application seeks to push the weight floor lower still, covering children in the same 4-and-older age band who weigh between 13 and 27 kilograms, a population currently excluded from labeled use because of their smaller size.
The Clinical Evidence Behind the Filing
The sNDA is supported by data from an open-label, multinational, single-arm Phase 3 study lasting 12 weeks in the relevant weight and age group, which the company says showed reductions in lymphadenopathy (swollen lymph nodes, a hallmark symptom of APDS) and increases in naive B cells, a marker of improved immune function. APDS is a rare, inherited immune disorder that the company describes as affecting roughly one to two people per million worldwide, with a median diagnostic delay of about seven years due to its rarity and symptom overlap with other immune conditions.
Company Statement
Pharming's Chief Medical Officer, Anurag Relan, said the review milestone brings the company closer to reaching smaller children currently ineligible for Joenja treatment because of the drug's weight-based labeling restrictions. Pharming is headquartered in Leiden, the Netherlands, and its shares trade on both Euronext Amsterdam and Nasdaq under related ticker symbols.
What APDS Is and Why Treatment Matters
Activated PI3K-delta syndrome is a rare primary immunodeficiency caused by a genetic mutation that leads to dysfunction of the immune system, leaving patients prone to recurrent infections, lymphoproliferation, and an increased risk of lymphoma. Because it was only characterized as a distinct disease in 2013, awareness among physicians has historically been limited, which the company says contributes to the long average diagnostic delay. Joenja, a PI3K-delta and Gamma inhibitor, was among the first therapies specifically approved to treat the underlying cause of APDS rather than only its symptoms and complications.
What the Filing Does Not Say
The 6-K does not disclose the specific number of patients enrolled in the supplemental study beyond describing it as multinational, nor does it provide detailed statistical results such as p-values or confidence intervals for the reported reductions in lymphadenopathy and increases in naive B cells. It also does not address pricing or reimbursement plans for the expanded label if approved, or how large the eligible patient population in the 13-to-27-kilogram weight band is expected to be.
The Road to the January 2027 PDUFA Decision
The FDA's PDUFA target action date of January 30, 2027 is the key date ahead, marking the point by which the agency intends to complete its review and either approve the label expansion or issue a complete response letter. The filing does not disclose whether an FDA advisory committee meeting will be convened as part of the review.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...